Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors

Conclusion Clinical markers are not useful to predict response to everolimus. However, occurrence of hypercholesterolemia under treatment may be an early marker of response. Prospective studies are required to confirm these results and to assess whether p-p70S6K immunostaining is a prognostic or predictive marker of no-response to everolimus.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research